# A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

> **NCT07215975** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (estimated)

## Conditions studied

- β-thalassemia

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT07215975
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2030-02-28
- **Final completion:** 2031-04-17
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215975, "A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*